Loading stock data…
Nuvation Bio Inc (NUVB)
$5.61
Market Closed
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $83.23M↑ | $41.87M↑ | $13.12M↑ | $4.83M↑ | $3.08M |
| Gross Profit | $77.24M↑ | $40.59M↑ | $9.77M↑ | $2.26M↑ | $990,000 |
| Operating Income | $3.88M↑ | -$34.04M↑ | -$56.43M↑ | -$63.59M↓ | -$59.00M |
| Net Income | $5.40M↑ | -$36.59M↑ | -$55.79M↑ | -$59.01M↓ | -$53.24M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ n...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.78B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-45.69%
Volume
Today's trading volume
-
Recent News
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Correction: Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks
(Corrects the third paragraph to state that May advance trade deficit widened.) The broad market
Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.7%, and the actively t
Nuvation Bio Prices $250 Million Convertible Bond Offering
Nuvation Bio (NUVB) has priced its underwritten offering of $250 million of 0.75% convertible senio
Why Is NUVB Stock Falling Today?
Nuvation Bio announced its intention to raise up to $230 million via a convertible senior notes offering.